Survival of hemodialysis patients and uremic toxin removal

Artificial Organs

Volumn 27, Issue 3, 2003, Pages 218-223

  Vanholder, Raymond ^a   De Smet, R ^a   Glorieux, G ^a   Dhondt, A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hemodialysis; Solute removal; Uremic toxin removal

Indexed keywords

BIOCOMPATIBILITY; DISEASES; DRUG DELIVERY; HEMODIALYZERS; METABOLISM; MOLECULES; PORE SIZE; PROTEINS; TOXIC MATERIALS; UREA;

CLASSIFIEDS; DIALYSATES; DIFFUSION-CONVECTION; HAEMODIALYSIS; HEMODIALYSIS PATIENT; SOLUTE REMOVAL; UREMIC TOXIN REMOVAL; UREMIC TOXINS; WATER SOLUBLE COMPOUNDS; WATER-SOLUBLE SOLUTES;

DIALYSIS;

ADRENOMEDULLIN; ANGIOGENIN; ATRIAL NATRIURETIC FACTOR; BETA 2 MICROGLOBULIN; BETA ENDORPHIN; BETA LIPOTROPIN; CHOLECYSTOKININ; CLARA CELL PROTEIN; COMPLEMENT FACTOR D; CYSTATIN C; CYTOKINE; DELTA SLEEP INDUCING PEPTIDE; ENDOTHELIN; HOMOCYSTEINE; HYPOXANTHINE; INDICAN; LEPTIN; METENKEPHALIN; NEUROPEPTIDE Y; PARA CRESOL; PHOSPHATE; POTASSIUM; RETINOL BINDING PROTEIN; UREA; UREMIC TOXIN; XANTHINE;

ARTIFICIAL MEMBRANE; BIOCOMPATIBILITY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIALYSATE; DIFFUSION; HEMODIALYSIS; INFLAMMATION; MALNUTRITION; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; POROSITY; PRIORITY JOURNAL; SOLUTE; SURVIVAL;

EID: 0037357696     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.2003.07212.x     Document Type: Conference Paper

References (42)

1. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-23.
2. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML. Uremic toxicity: present state of the art. Int J Artif Organs 2001;24:695-725.
3. Vanholder RC, Ringoir SM. Adequacy of dialysis: a critical analysis. Kidney Int 1992;42:540-58.
4. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-34.
5. Babb AL, Ahmad S, Bergstrom J, Scribner BH. The middle molecule hypothesis in perspective. Am J Kidney Dis 1981;1:46-50.
6. Covic A, Goldsmith DJ, Hill K, Venning MC, Ackrill P. Urea kinetic modelling - are any of the 'bedside' Kt/V formulae reliable enough? Nephrol Dial Transplant 1998;13:3138-46.
7. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001-6.
8. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones CA, Greer JW, Golper TA, Held PJ. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996;50:557-65.
9. NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. Am J Kidney Dis 1997;30:S15-66.
10. I. NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kidney Dis 2001;37:S7-64.
11. Deziel C, Hirsch DJ, Hoult P, Levin A, Sohi P, Taub KJ, Watson D. Clinical practice guidelines for the delivery of hemodialysis. Canadian Society of Nephrology. J Am Soc Nephrol 1999;10(Suppl13):S306-10.
12. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G. Survival as an index of adequacy of dialysis. Kidney Int 1992;41:1286-91.
13. Shinzato T, Nakai S, Akiba T, Yamazaki C, Sasaki R, Kitaoka T, Kubo K, Shinoda T, Kurokawa K, Marumo F, Sato T, Maeda K. Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 1997;12:884-8.
14. Sehgal AR, Dor A, Tsai AC. Morbidity and cost implications of inadequate hemodialysis. Am J Kidney Dis 2001;37:1223-31.
15. Chertow GM, Owen WF, Lazarus JM, Lew NL, Lowrie EG. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999;56:1872-8.
16. Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, Port FK. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 2000;35:80-8.
17. Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 1972;47:21-9.
18. Vanholder RC, De Smet RV, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. Clin Chem 1992;38:1429-36.
19. Bleyer AJ, Russell GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int 1999;55:1553-9.
20. Locatelli F, Marcelli D, Conte F, Limido A, Malberti F, Spotti D. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 1999;55:286-93.
21. Bloembergen WE, Hakim RM, Stannard DC, Held PJ, Wolfe RA, Agodoa LY, Port FK. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999;33:1-10.
22. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996;334:420-5.
23. Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995;5:1703-8.
24. Gutierrez A, Alvestrand A, Wahren J, Bergstrom J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990;38:487-94.
25. Tattersall JE, Cramp M, Shannon M, Farrington K, Greenwood RN. Rapid high-flux dialysis can cure uraemic peripheral neuropathy. Nephrol Dial Transplant 1992;7:539-40.
26. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997;30:366-73.
27. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-101.
28. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJ, Agodoa LY, Port FK. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999;33:349-55.
29. Port FK, Wolfe RA, Hulbert-Shearon TE, Daugirdas JT, Agodoa LY, Jones C, Orzol SM, Held PJ. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS dialysis morbidity and mortality study. Am J Kidney Dis 2001;37:276-86.
30. Greene T, Beck GJ, Gassman JJ, Gotch FA, Kusek JW, Levey AS, Levin NW, Schulman G, Eknoyan G. Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials 2000;21:502-25.
31. Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R. The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol 1999;12:85-8.
32. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999;55:1945-51.
33. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-76.
34. Schouten WE, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 2000;15:379-84.
35. Vanholder R, De Smet R, Lesaffer G. P-Cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrol Dial Transplant 1999;14:2813-5.
36. De Smet R, David F, Sandra P, Van Kaer J, Lesaffer G, Dhondt A, Lameire N, Vanholder R. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998;278:1-21.
37. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50-7.
38. De Smet R, Van Kaer J, Van Vlem B, Lameire N, Vanholder R. A decrease of serum albumin increases the free concentration of p-cresol and its toxicity. J Am Soc Nephrol 2001;12:375A (abstract).
39. Mailloux LU, Bellucci AG, Wilkes BM, Napolitano B, Mossey RT, Lesser M, Bluestone PA. Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 1991;18:326-35.
40. Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 2000;36:820-5.
41. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
42. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911.